Next Article in Journal
Tetrodotoxin Sensitivity of the Vertebrate Cardiac Na+ Current
Next Article in Special Issue
Advancement into the Arctic Region for Bioactive Sponge Secondary Metabolites
Previous Article in Journal
Isolation and Identification of a New Tetrodotoxin-Producing Bacterial Species, Raoultella terrigena, from Hong Kong Marine Puffer Fish Takifugu niphobles
Previous Article in Special Issue
Examination of Marine-Based Cultivation of Three Demosponges for Acquiring Bioactive Marine Natural Products
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2011, 9(11), 2397-2408; doi:10.3390/md9112397

Neoamphimedine Circumvents Metnase-Enhanced DNA Topoisomerase IIα Activity Through ATP-Competitive Inhibition

1
Department of Pharmaceutical Sciences, The University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, Aurora, CO 80045,USA
2
Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA
3
Department of Medicine, University of Florida and Shands Health Care System, Gainesville, FL 32610, USA
*
Author to whom correspondence should be addressed.
Received: 6 September 2011 / Revised: 8 November 2011 / Accepted: 9 November 2011 / Published: 18 November 2011
(This article belongs to the Special Issue Bioactive Compounds from Marine Sponges)
View Full-Text   |   Download PDF [904 KB, uploaded 24 February 2015]   |  

Abstract

Type IIα DNA topoisomerase (TopoIIα) is among the most important clinical drug targets for the treatment of cancer. Recently, the DNA repair protein Metnase was shown to enhance TopoIIα activity and increase resistance to TopoIIα poisons. Using in vitro DNA decatenation assays we show that neoamphimedine potently inhibits TopoIIα-dependent DNA decatenation in the presence of Metnase. Cell proliferation assays demonstrate that neoamphimedine can inhibit Metnase-enhanced cell growth with an IC50 of 0.5 µM. Additionally, we find that the apparent Km of TopoIIα for ATP increases linearly with higher concentrations of neoamphimedine, indicating ATP-competitive inhibition, which is substantiated by molecular modeling. These findings support the continued development of neoamphimedine as an anticancer agent, particularly in solid tumors that over-express Metnase.
Keywords: neoamphimedine; topoisomerase II; Metnase; cancer therapeutics neoamphimedine; topoisomerase II; Metnase; cancer therapeutics
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ponder, J.; Yoo, B.H.; Abraham, A.D.; Li, Q.; Ashley, A.K.; Amerin, C.L.; Zhou, Q.; Reid, B.G.; Reigan, P.; Hromas, R.; Nickoloff, J.A.; LaBarbera, D.V. Neoamphimedine Circumvents Metnase-Enhanced DNA Topoisomerase IIα Activity Through ATP-Competitive Inhibition. Mar. Drugs 2011, 9, 2397-2408.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top